Comparison of Cefazolin versus Oxacillin for Treatment of Complicated Bacteremia Caused by Methicillin-Susceptible Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Contrary to prior case reports that described occasional clinical failures with cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infections, recent studies have demonstrated no difference in outcomes between cefazolin and antistaphylococcal penicillins for the treatment of MSSA bacteremia. While promising, these studies described low frequencies of high-inoculum infections, such as endocarditis. This retrospective study compares clinical outcomes of cefazolin versus oxacillin for complicated MSSA bacteremia at two tertiary care hospitals between January 2008 and June 2012. Fifty-nine patients treated with cefazolin and 34 patients treated with oxacillin were included. Osteoarticular (41%) and endovascular (20%) sources were the predominant sites of infection. The rates of clinical cure at the end of therapy were similar between cefazolin and oxacillin (95% versus 88%; P = 0.25), but overall failure at 90 days was higher in the oxacillin arm (47% versus 24%; P = 0.04). Failures were more likely to have received surgical interventions (63% versus 40%; P = 0.05) and to have an osteoarticular source (57% versus 33%; P = 0.04). Failures also had a longer duration of bacteremia (7 versus 3 days; P = 0.0002), which was the only predictor of failure. Antibiotic selection was not predictive of failure. Rates of adverse drug events were higher in the oxacillin arm (30% versus 3%; P = 0.0006), and oxacillin was more frequently discontinued due to adverse drug events (21% versus 3%; P = 0.01). Cefazolin appears similar to oxacillin for the treatment of complicated MSSA bacteremia but with significantly improved safety. The higher rates of failure with oxacillin may have been confounded by other patient factors and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Staphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy
Tice, A. D., Rehm, S. J., Dalovisio, J. R., Bradley, J. S., Martinelli, L. P., Graham, D. R., Gainer, R. B., Kunkel, M. J., Yancey, R. W., & Williams, D. N. (2004) · Clinical Infectious Diseases · doi:10.1086/420939 · Cited by 532
Paul, M., Zemer-Wassercug, N., Talker, O., Lishtzinsky, Y., Lev, B., Samra, Z., Leibovici, L., & Bishara, J. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03425.x · Cited by 188
Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcome
Khatib, R., Johnson, L. B., Fakih, M. G., Riederer, K., Khosrovaneh, A., Shamse Tabriz, M., Sharma, M., & Saeed, S. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540500372846 · Cited by 168
Hawkins, C. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.17.1861 · Cited by 166
Nannini, E. C., Stryjewski, M. E., Singh, K. V., Bourgogne, A., Rude, T. H., Corey, G. R., Fowler, V. G., & Murray, B. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00317-09 · Cited by 160
Lee, S., Choe, P. G., Song, K.-H., Park, S.-W., Kim, H. B., Kim, N. J., Kim, E.-C., Park, W. B., & Oh, M.-D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-11 · Cited by 128
Chong, Y. P., Park, S., Kim, H. S., Kim, E. S., Kim, M., Park, K., Kim, S., Lee, S., Choi, S., Jeong, J., et al. (2013) · Medicine · doi:10.1097/md.0b013e318289ff1e · Cited by 125
Nannini, E. C., Singh, K. V., & Murray, B. E. (2003) · Clinical Infectious Diseases · doi:10.1086/379021 · Cited by 103
Youngster, I., Shenoy, E. S., Hooper, D. C., & Nelson, S. B. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu301 · Cited by 96
Unsuccessful Treatment of Staphylococcal Endocarditis With Cefazolin
Bryant, R. E. (1977) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1977.03270330059022 · Cited by 86
Clinical Experiences with Cefazolin and Other Cephalosporins in Bacterial Endocarditis
Quinn, E. L., Pohlod, D., Madhavan, T., Burch, K., Fisher, E., & Cox, F. (1973) · Journal of Infectious Diseases · doi:10.1093/infdis/128.supplement_2.s386 · Cited by 68
Neuner, E. A., Casabar, E., Reichley, R. M., & McKinnon, P. S. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.02.026 · Cited by 67
Valour, F., Karsenty, J., Bouaziz, A., Ader, F., Tod, M. M., Lustıg, S., Laurent, F. J., Écochard, R., Chidiac, C., & Ferry, T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02032-13 · Cited by 67
Lee, S., Kwon, K. T., Kim, H. I., Chang, H., Lee, J., Choe, P. G., Park, W. B., Kim, N. J., Oh, M., Song, D. Y., et al. (2014) · Microbial Drug Resistance · doi:10.1089/mdr.2013.0229 · Cited by 64
Nannini, E. C., Singh, K. V., Arias, C. A., & Murray, B. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00856-13 · Cited by 64 · cited 2×
“16 Relapse of infection 7/30 (23) 3/16 (19) 4/14 (29) 1.”
BackgroundLivorsi, D. J., Crispell, E. K., Satola, S. W., Burd, E. M., Jerris, R. C., Wang, Y. F., & Farley, M. M. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-12 · Cited by 59
Rincón, S., Reyes, J., Carvajal, L. P., Rojas, N., Cortés-Muñoz, F., Panesso, D., Guzman, M., Zurita, J., Adachi, J. A., Murray, B. E., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt254 · Cited by 58
Maraqa, N. F., Gomez, M. M., Rathore, M. H., & Alvarez, A. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338047 · Cited by 51
Liao, C.-H., Chen, S.-Y., Huang, Y.-T., & Hsueh, P.-R. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.04.011 · Cited by 40
Cefazolin Therapy for Staphylococcus aureus Bacteremia
Fernández-Guerrero, M. L., & Górgolas, M. (2005) · Clinical Infectious Diseases · doi:10.1086/430833 · Cited by 36
Adverse drug reactions in home care patients receiving nafcillin or oxacillin
Dahlgren, A. F. (1997) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/54.10.1176 · Cited by 22
Hepatic and Renal Dysfunction following Nafcillin Administration
Lestico, M. R., Vick, K., & Hetsko, C. M. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600724 · Cited by 12
Research works printed but not linked: 5
- Echevarria K, Childs L, Oates E, Cadena J. 2012. Antibiotic stewardship involving anti-staphylococcal beta-lactams at a Veterans Affairs hospital. Abstr. IDWeek 2012, abstr 34750. [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Abstr.%20IDWeek%202012,%20abstr%2034750&title=Antibiotic%20stewardship%20involving%20anti-staphylococcal%20beta-lactams%20at%20a%20Veterans%20Affairs%20hospital&author=K%20Echevarria&author=L%20Childs&author=E%20Oates&author=J%20Cadena&publication_year=2012&)]
- Lewis JS, II, Bowling JE, Laurel Y, Jorgensen JH. 2012. Clinical and financial impact of the replacement of oxacillin with cefazolin for MSSA infections. Abstr. IDWeek 2012, abstr 739. [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Abstr.%20IDWeek%202012,%20abstr%20739&title=Clinical%20and%20financial%20impact%20of%20the%20replacement%20of%20oxacillin%20with%20cefazolin%20for%20MSSA%20infections&author=JS%20Lewis&author=JE%20Bowling&author=Y%20Laurel&author=JH%20Jorgensen&publication_year=2012&)]
- Nevrekar S, Rhodes N, Crank C, Scheetz MH, Pavell A, Segreti J, Wang S. 2013. Treatment outcomes of cefazolin versus oxacillin for high burden methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections (BSI). Abstr. IDWeek 2013, abstr 1731. [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Abstr.%20IDWeek%202013,%20abstr%201731&title=Treatment%20outcomes%20of%20cefazolin%20versus%20oxacillin%20for%20high%20burden%20methicillin-sensitive%20Staphylococcus%20aureus%20(MSSA)%20bloodstream%20infections%20(BSI)&author=S%20Nevrekar&author=N%20Rhodes&author=C%20Crank&author=MH%20Scheetz&author=A%20Pavell&publication_year=2013&)]
- Huang M, Knepper B, Haas M, Jenkins T. 2013. Effects of an intervention to substitute cefazolin for nafcillin in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia. Abstr. IDWeek 2013, abstr 1017. [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Abstr.%20IDWeek%202013,%20abstr%201017&title=Effects%20of%20an%20intervention%20to%20substitute%20cefazolin%20for%20nafcillin%20in%20selected%20cases%20of%20methicillin-susceptible%20Staphylococcus%20aureus%20bacteremia&author=M%20Huang&author=B%20Knepper&author=M%20Haas&author=T%20Jenkins&publication_year=2013&)]
- Nuibe A, Olson J, Hersh A, Stockmann C, Sanderson S, Pavia A, Thorell EA. 2013. Costs and outcomes for children with methicillin-susceptible Staphylococcus aureus osteoarticular infections with bacteremia. Abstr. IDWeek 2013, abstr 421. [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Abstr.%20IDWeek%202013,%20abstr%20421&title=Costs%20and%20outcomes%20for%20children%20with%20methicillin-susceptible%20Staphylococcus%20aureus%20osteoarticular%20infections%20with%20bacteremia&author=A%20Nuibe&author=J%20Olson&author=A%20Hersh&author=C%20Stockmann&author=S%20Sanderson&publication_year=2013&)]
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Chaves, F., Garnacho-Montero, J., del Pozo, J. L., Bouza, E., Capdevila, J. A., de Cueto, M., Domínguez, M. Á., Esteban, J., Fernández-Hidalgo, N., Fernández Sampedro, M., et al. (2018) · Medicina Intensiva · doi:10.1016/j.medin.2017.09.012 · Cited by 170
McDanel, J. S., Roghmann, M., Perencevich, E. N., Ohl, M., Goto, M., Livorsi, D. J., Jones, M., Albertson, J., Nair, R., O’Shea, A. M. J., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix287 · Cited by 157
Weis, S., Kesselmeier, M., Davis, J. S., Morris, A. M., Lee, S., Scherag, A., Hagel, S., & Pletz, M. W. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.010 · Cited by 127
Miller, W. R., Seas, C., Carvajal, L. P., Díaz, L., Echeverri, A. M., Ferro, C., Ríos, R., Porras, P., Luna, C. M., Gotuzzo, E., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy123 · Cited by 116
Metadata
- Authors
- Li, J., Echevarria, K. L., Hughes, D. W., Cadena, J. A., Bowling, J. E., & Lewis, J. S.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-09
- Volume
- 58
- Issue
- 9
- Pages
- 5117-5124
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC4135867
- OpenAlex
- W2168149280
- Semantic Scholar
- dd246878d23fb3747e00201e22c14f020dad911e
- Cited by
- 117
- References
- 25
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 3 · 2023: 5 · 2022: 12 · 2021: 8 · 2020: 10 · 2019: 10 · 2018: 23 · 2017: 13 · 2016: 10 · 2015: 6 · 2014: 1
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Texas ScholarWorks (Texas Digital Library) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- cefazolin, oxacillin, methicillin-susceptible Staphylococcus aureus, complicated bacteremia, antibiotic treatment failure, adverse drug reactions, bone and joint infections, endovascular infection, duration of bacteremia, surgical treatment, antibiotic selection
- MeSH terms
- Anti-Bacterial Agents, Cefazolin, Female, Humans, Male, Methicillin, Microbial Sensitivity Tests, Middle Aged, Oxacillin, Retrospective Studies, Staphylococcal Infections, Staphylococcus aureus, Bacteremia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.